SCHEMBL2197402

SCHEMBL2197402

IN(I)Cc1ccccc1.[Pt]=c1n(Cc2ccccc2)ccn1Cc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CYP11B1 P15538 2/20 0.38
CYP11B2 P19099 2/20 0.38
TNF P01375 1/20 0.38
DBH P09172 1/20 0.38
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HTR6 P50406 1/20 0.36
TSHR P16473 1/20 0.35
NOTUM Q6P988 1/20 0.35
MAPK14 Q16539 2/20 0.35
SIGMAR1 Q99720 1/20 0.34
LMNA P02545 2/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
TP53 P04637 1/20 0.34
CYP2D6 P10635 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2193549 0.92 SIGMAR1 (0.42) ALDH1A1KDM4ECYP11B1CYP11B2DBH
SCHEMBL2191713 0.91 CYP11B1 (0.40) ALDH1A1KDM4EL3MBTL1CYP11B1CYP11B2
SCHEMBL2194579 0.91 CNR2 (0.41) ALDH1A1KDM4EL3MBTL1CYP11B1CYP11B2
SCHEMBL2195700 0.91 MAPT (0.45) ALDH1A1KDM4ECYP11B1CYP11B2HDAC8
SCHEMBL2196798 0.87 BCHE (0.41) ALDH1A1KDM4EHTR6SIGMAR1LMNA
SCHEMBL2195793 0.84 LMNA (0.42) ALDH1A1KDM4EL3MBTL1NOTUMLMNA
SCHEMBL2194976 0.80 SIGMAR1 (0.44) L3MBTL1CYP11B1CYP11B2TSHRSIGMAR1
SCHEMBL2193845 0.79 POLB (0.39) ALDH1A1KDM4EHTR6LMNAMAPT
SCHEMBL2192049 0.79 KDM4E (0.37) ALDH1A1KDM4EL3MBTL1CYP11B1CYP11B2
SCHEMBL2195569 0.78 CNR1 (0.37) ALDH1A1KDM4EL3MBTL1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 ALDH1A1 1989/4885KDM4E 4803/4885L3MBTL1 2187/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 ALDH1A1 1989/4885KDM4E 4803/4885L3MBTL1 2187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.